Back to results
US 12,564,633 B2Granted
Oncolytic virus strain
AssigneeReplimune Limited
InventorRobert Stuart Coffin
Life of this patent
Estimating the term…
Abstract
The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.
Claims9
An oncolytic virus which is a modified herpes simplex virus (HSV) 1 strain:
- RH018A having the accession number ECACC 16121904;
- RH004A having the accession number ECACC 16121902;
- RH031A having the accession number ECACC 16121907;
- RH040B having the accession number ECACC 16121908;
- RH015A having the accession number ECACC 16121903;
- RH021A having the accession number ECACC 16121905;
- RH023 A having the accession number ECACC 16121906;
- or
- RH047A having the accession number ECACC 16121909,
- wherein said virus is modified to delete or alter expression of one or more viral genes and to express one or more heterologous genes.
7 more elements
Dependencies are inferred from the claim text.